您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > ML390
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
ML390
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
ML390图片
CAS NO:2029049-79-2
规格:≥98%
包装与价格:
包装价格(元)
5mg电议
10mg电议
25mg电议
50mg电议
100mg电议
250mg电议
500mg电议

产品介绍
理化性质和储存条件
Molecular Weight (MW)406.4
FormulaC21H21F3N2O3
CAS No. 2029049-79-2
Storage-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)DMSO: 81 mg/mL (199.3 mM)
Water: <1 mg/mL
Ethanol: 60 mg/mL (147.6 mM)
SoMILESO=C(NCCC(N[C@@H]1CCCC2=C1C=CC=C2)=O)C3=CC([H])=C(OC(F)(F)F)C=C3
SynonymsML390; ML-390 ML 390
实验参考方法
In Vitro

In vitro activity: In the screening study, ML390 was identified as the most potent compound against the engineered ERHOX-GFP cell line. Moreover, the addition of uridine to the cell culture media could abrogate the differentiation effects of ML390, demonstrating further evidences that ML390’ effects were due to their inhibition of DHODH-catalyzed pyrimidine synthesis. In addition, ML390 was found to be not able to inhibit DHODH in the P. falciparum parasite, which is the causative agent of malaria. Furthermore, the X-ray structure indicated that the binding of ML390 to the enzyme might be increased by modifying ML390 with a ring in its central portion to lock the molecule into its binding conformation with the amide substituents.


Kinase Assay: ML390 is a novel potent inhibitor of human DHODH (Dihydroorotate dehydrogenase) that induces differentiation in acute myeloid leukemia (AML) with EC50 of 1.8μM, 8.8μM, 6.5μM, and 0.56μM in ER-HOX-GFP, U937, THP-1 cells and DHODH enzyme, respectively. ML390 was identified as the most potent compound against the engineered ERHOX-GFP cell line. Moreover, the addition of uridine to the cell culture media could abrogate the differentiation effects of ML390, demonstrating further evidences that ML390’ effects were due to their inhibition of DHODH-catalyzed pyrimidine synthesis. Therefore, ML390 may offer insight into the mechanism of overcoming differentiation arrest, and has the potential to used as a treatment for patients with AML.


Cell Assay: Lys-GFP-ER-HoxA9 cells were treated in culture with 10 μM ML390 for 48 hr. The cells were washed three times in normal saline, and metabolites were extracted into 80% ice-cold methanol. Metabolites were analyzed. Negative ionization mode analyses of polar metabolites were acquired using an LC-MS system comprising an Acquity UPLC System (Waters) and a 5500 QTrap triple quadrupole mass spectrometer (AB SCIEX). Samples for negative ion mode analyses of polar metabolites were achieved using the HILIC (hydrophilic interaction chromatography) method under basic conditions as described previously, and MS data were acquired over m/z 70-750. MS data were processed using MultiQuant.

In Vivo
Animal model
Formulation & Dosage
ReferencesACS Med Chem Lett. 2016 Sep 28;7(12):1112-1117; Cell. 2016 Sep 22;167(1):171-186.e15.